Evommune's second quarter of 2026 is the financial statement of a clinical-stage immunology company at an inflection point between disappointment and possibility. The company's lead candidate, EVO756, failed its Phase 2b trial in chronic spontaneous urticaria, missing the primary endpoint at every dose, and Evommune has stopped developing the drug in that indication. But the same molecule is still being tested in atopic dermatitis, with results expected in September 2026, and in migraine, with results expected in 2027, and a second candidate, EVO301, is moving toward a Phase 2b trial in atopic dermatitis planned for mid-2027. The stock trades at $13.67, well below a 52-week high of $33.20 and just above a low of $10.47, with a market capitalization of roughly $496 million, no earnings, and no dividend.
The financials are the story of a pre-revenue biotech burning cash to run trials and funding itself through equity raises. The company had zero revenue in the second quarter and the first half of 2026, against $3,000 of revenue a year earlier. Research and development expense rose to $26.4 million in the quarter from $19.6 million, and general and administrative expense more than doubled to $8.5 million from $3.4 million. The net loss was $32.2 million against $13.6 million a year ago, and for the first half the loss was $53.9 million against $28.1 million. The widening loss reflects the cost of running more trials, and it is the expected financial shape of a company advancing multiple Phase 2 programs at once.
What keeps the story alive is the balance sheet. Evommune held $288 million in cash, cash equivalents, and investments as of June 30, 2026, and it says that position will fund operating expenses and capital expenditures through 2028 based on the current business plan. The company also raised $117.2 million in a private placement in February 2026, selling 4.5 million shares at $27.88 each, which is well above the current price of $13.67. That placement is the signal that sophisticated investors were willing to fund the pipeline at a price more than double where the stock trades now, and it is the single most important data point in the valuation story.
The investment question is binary in the way biotech questions are: the value of the company depends almost entirely on whether EVO756 works in atopic dermatitis, with results in September 2026, and whether EVO301 advances as planned. The cash runway through 2028 means the company does not need to raise money before those readouts, which removes the dilution risk that typically pressures pre-data biotech stocks. But the stock's fall from $33.20 to $13.67 is the market's verdict on the urticaria failure and its uncertainty about what comes next. The next few weeks, as the atopic dermatitis data approaches, will determine whether the current price is a discount to a still-viable pipeline or a fair reflection of a damaged one.